In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses

被引：0
|
作者：
Le Hingrat, Q. [1 ]
Collin, G. [1 ]
Damond, F. [1 ]
Peytavin, G. [2 ]
Lebourgeois, S. [1 ]
Ghosn, J. [3 ]
Bachelard, A. [3 ]
Ferre, V. [1 ]
Matheron, S. [3 ]
Descamps, D. [1 ]
Charpentier, C. [1 ]
机构：
[1] Hop Bichat Claude Bernard, AP HP, Lab Virol, Paris, France
[2] Hop Bichat Claude Bernard, AP HP, Lab Pharmacol, Paris, France
[3] Hop Bichat Claude Bernard, AP HP, Serv Malad Infect & Trop, Paris, France
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
E13/27
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [31] In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene
    Damond, F
    Collin, G
    Matheron, S
    Peytavin, G
    Campa, P
    Delarue, S
    Taieb, A
    Bénard, A
    Chêne, G
    Brun-Vézinet, F
    Descamps, D
    ANTIVIRAL THERAPY, 2005, 10 (07) : 861 - 865
  • [32] In vitro phenotypic susceptibility of HIV-1 non-B integrase inhibitor naive clinical isolates to dolutegravir and raltegravir
    Charpentier, C.
    Bertine, M.
    Visseaux, B.
    Leleu, J.
    Larrouy, L.
    Peytavin, G.
    Collin, G.
    Brun-Vezinet, F.
    Plantier, J. C.
    Descamps, D.
    ANTIVIRAL THERAPY, 2013, 18 : A106 - A106
  • [33] Baseline susceptibility of primary HIV-2 to entry inhibitors
    Borrego, Pedro
    Calado, Rita
    Marcelino, Jose M.
    Bartolo, Ines
    Rocha, Cheila
    Cavaco-Silva, Patricia
    Doroana, Manuela
    Antunes, Francisco
    Maltez, Fernando
    Caixas, Umbelina
    Barroso, Helena
    Taveira, Nuno
    ANTIVIRAL THERAPY, 2012, 17 (03) : 565 - 570
  • [34] ORIGINS OF THE AIDS VIRUSES - HIV-1 AND HIV-2, FACT OR FICTION
    SEALE, J
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1989, 82 (08) : 508 - 508
  • [35] ORIGINS OF THE AIDS VIRUSES, HIV-1 AND HIV-2 - FACT OR FICTION
    DALE, BAS
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1989, 82 (04) : 243 - 244
  • [36] Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir
    Charpentier, Charlotte
    Roquebert, Benedicte
    Delelis, Olivier
    Larrouy, Lucile
    Matheron, Sophie
    Tubiana, Roland
    Karmochkine, Marina
    Duval, Xavier
    Chene, Genevieve
    Storto, Alexandre
    Collin, Gilles
    Benard, Antoine
    Damond, Florence
    Mouscadet, Jean-Francois
    Brun-Vezinet, Francoise
    Descamps, Diane
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (03) : 1293 - 1295
  • [37] In vitro replication capacity of HIV-2 variants from long-term aviremic individuals
    Blaak, Hetty
    van der Ende, Marchina E.
    Boers, Patrick H. M.
    Schuitemaker, Hanneke
    Osterhaus, Albert D. M. E.
    VIROLOGY, 2006, 353 (01) : 144 - 154
  • [38] Conserved CXCR4 usage and enhanced replicative capacity of HIV-2/287, an isolate highly pathogenic in Macaca nemestrina
    Rey-Cuille, MA
    Hu, SL
    AIDS, 2001, 15 (18) : 2349 - 2357
  • [39] In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir
    Charpentier, Charlotte
    Bertine, Melanie
    Visseaux, Benoit
    Leleu, Juliette
    Larrouy, Lucile
    Peytavin, Gilles
    Mourez, Thomas
    Collin, Gilles
    Brun-Vezinet, Francoise
    Plantier, Jean-C.
    Descamps, Diane
    AIDS, 2013, 27 (18) : 2959 - 2961
  • [40] SYNTHESIS OF CURDLAN SULFATES HAVING INHIBITORY EFFECTS IN-VITRO AGAINST AIDS VIRUSES HIV-1 AND HIV-2
    YOSHIDA, T
    YASUDA, Y
    MIMURA, T
    KANEKO, Y
    NAKASHIMA, H
    YAMAMOTO, N
    URYU, T
    CARBOHYDRATE RESEARCH, 1995, 276 (02) : 425 - 436
12345